Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Estradiol transdermal micro patch - Noven Pharmaceuticals

Drug Profile

Estradiol transdermal micro patch - Noven Pharmaceuticals

Alternative Names: Estradot; Minivelle; Vivelle-Dot

Latest Information Update: 28 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Noven Pharmaceuticals
  • Developer Novartis; Noven Pharmaceuticals
  • Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Atrophic vaginitis; Menopausal syndrome; Postmenopausal osteoporosis; Primary ovarian insufficiency; Vasomotor symptoms

Most Recent Events

  • 07 Nov 2017 Noven Pharmaceuticals initiates litigation against Alvogen over ANDA submission in USA
  • 05 May 2015 Noven Pharmaceuticals and Hisamitsu Pharmaceutical filed first-to-file patent-challenge lawsuit relating to the generic version of Minivelle® in the US against Mylan N.V. and its subsidiaries
  • 18 Feb 2015 Launched for Postmenopausal osteoporosis (Prevention) in the US (Transdermal, Minivelle® 0.025 mg/day)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top